Page 4 - THEALOZ DUO LEAFLET CONGRES 2021_Slide

FOR PATIENTS WITH DRY EYES

TREHALOSE 3% | HYALURONIC ACID 0.15% MEDICAL DEVICE

Clinical proven efficacy

GREATER IMPROVEMENT IN OSDI WITH THEALOZ DU VS HA 12 GREATER PATIENT SATISFACTION

• Thealoz Duo shows better improvement in the OSDI scores than HA alone 12
®

Change from baseline OSDI scores and distribution in the
OSDI categories on day 84

100 p =0.044
76.9 11.5 71.7 18.9 HA-trehalose
90 7.7 None: OSDI [0-13]
Mild: OSDI [13-23]
80 7.5 Moderate: OSDI [23-33]
19.2 34 Severe: OSDI [33-100]
70
% of patients 60 61.5 HA None: OSDI [0-13]
Mild: OSDI [13-23]
50
Moderate: OSDI [23-33]
40
Severe: OSDI [33-100]
30
22.6 39.6
20 19.2
10
0 3.8 5.7
D0 D84 D0 D84
N=105 patients with moderate-to-severe dry eye.
Randomised, active-controlled, investigator-masked, multicentric study.
Patients received either Thealoz ® Duo (trehalose + hyaluronic acid) or hyaluronic acid 3-6 times a day for
84 days.

HA-trehalose HA HA-trehalose HA
p =0.015 p =0.023 HA-trehalose
100 100 Not very satisfactory/
9.6 28.3 13.5 32.1 Unsatisfactory
90 90
90.4 80 86.5 Very satisfactory/
80
Satisfactory
4 12. Chiambaretta F. et al; A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome
HA
70
70
Eur J Ophthalmol 2016. 71.7 60 67.9 Not very satisfactory/
% of patients 50 % of patients 50 Very satisfactory/
60
Unsatisfactory
Satisfactory
40
40
30
20
20 30
10 10
0 0
INVESTIGATOR’S PATIENT’S
ASSESSMENT ASSESSMENT
HA-trehalose
HA
*p =0.05